The FDA has approved label changes for buprenorphine extended-release (ER) injection (Sublocade, Indivior), including a rapid initiation protocol and alternative injection sites.
Healthcare providers can initiate treatment with buprenorphine ER after a single dose of transmucosal buprenorphine and a one-hour observation period to confirm tolerability. Buprenorphine ER also can be administered subcutaneously in the abdomen, thigh, buttock or back of the upper arm.
The FDA label changes can provide